Last reviewed · How we verify
Etonogestrel (ETG) implant
Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus.
Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus. Used for Contraception (prevention of pregnancy).
At a glance
| Generic name | Etonogestrel (ETG) implant |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Progestin contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | FDA-approved |
Mechanism of action
Etonogestrel is a synthetic progestin that acts on the hypothalamic-pituitary-ovarian axis to inhibit the LH surge necessary for ovulation. It also increases cervical mucus viscosity, creating a barrier to sperm penetration. The subdermal implant provides sustained hormone release over three years, maintaining contraceptive efficacy without daily administration.
Approved indications
- Contraception (prevention of pregnancy)
Common side effects
- Irregular bleeding or amenorrhea
- Headache
- Acne
- Breast tenderness
- Weight gain
- Mood changes
- Insertion site pain or infection
Key clinical trials
- Kuwa Free! - Live Free! (NA)
- Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
- Impact of Contraceptives on Cervico-Vaginal Mucosa (PHASE4)
- Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etonogestrel (ETG) implant CI brief — competitive landscape report
- Etonogestrel (ETG) implant updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI